PT-141 10 MG

PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide and a melanocortin receptor agonist, primarily targeting the MC3R and MC4R receptors in the central nervous system. It is developed for the treatment of sexual dysfunction, including female hypoactive sexual desire disorder (HSDD) and erectile dysfunction.

Pharmacokinetics and stability of PT-141 include:

• Rapid absorption after subcutaneous injection, with effects typically beginning within 30 minutes to an hour.
• A plasma half-life of approximately 2.7 hours, which influences the duration of its pharmacological effects lasting between 24 to 72 hours depending on the dose and individual metabolism.
• Enhanced peptide stability is partly due to its cyclic structure, N-terminal acetylation, and C-terminal amidation, which provide resistance against enzymatic degradation.
• Metabolism and clearance are influenced by liver function and protease activity, with variability in how individuals respond and process the peptide.
• PT-141 is generally well tolerated with a good safety profile based on clinical studies, with few adverse effects reported.
PT-141 is provided as a high-purity lyophilized powder for research use only (RUO) and is FDA-approved as Vyleesi for clinical use in women under prescription.

Product details:

• Amino Acid Sequence: Ac-Nle-cAsp-His-D-Phe-Arg-Trp-Lys-OH
• Molecular Formula: C50H68N14O10
• Molecular Weight: 1025.2 Da
• Appearance: White to off-white lyophilized powder
• Dosage: Typically 1-2 mg subcutaneous injection before sexual activity; max twice a week

PT-141 is an established peptide for research in sexual function modulation with notable pharmacokinetics and enhanced stability due to its chemical modifications.